###begin article-title 0
###xml 93 101 <span type="species:ncbi:9606">Patients</span>
Pattern of DAP12 Expression in Leukocytes from Both Healthy and Systemic Lupus Erythematosus Patients
###end article-title 0
###begin p 1
Conceived and designed the experiments: NS JRH FAMJ FV. Performed the experiments: LC SG GB AM. Analyzed the data: NS LC GB FAMJ FV. Contributed reagents/materials/analysis tools: JV EH GK. Wrote the paper: NS FV.
###end p 1
###begin p 2
###xml 601 609 <span type="species:ncbi:9606">patients</span>
###xml 715 723 <span type="species:ncbi:9606">patients</span>
DAP12 is an ITAM-bearing transmembrane adaptor originally identified on the surface of Natural Killer cells. A broad expression among other immune cells was later found in myeloid and lymphoid cells. However, data on DAP12 expression pattern rely only on immunoblot and microarray analysis. Here, we describe the generation and the characterization of an anti-DAP12 monoclonal antibody. Using this novel reagent, we show that DAP12 expression is restricted to innate immune cells in basal condition. Since a decreased expression of DAP12 has been suggested in NK cells of systemic lupus erythematosus patients, we have further investigated the NK cell receptor repertoire and leukocyte expression of DAP12 in these patients and no major changes were detectable when compared to controls.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 114 117 114 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Lanier1">[1]</xref>
###xml 119 122 119 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Olcese1">[2]</xref>
###xml 124 127 124 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Tomasello1">[3]</xref>
###xml 287 288 287 288 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sub>
###xml 709 712 709 712 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">syk</sup>
###xml 896 899 896 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Lanier2">[4]</xref>
###xml 901 904 901 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Tomasello2">[5]</xref>
DAP12 (DNAX Activating Protein of 12 kDa) is a transmembrane adaptor initially identified in Natural Killer cells [1], [2], [3]. This molecule is also named KARAP (Killer cell Activating Receptor-Associated Protein) or TYROBP (TYROsine kinase Binding Protein). The presence of a YxxL-(x)7-YxxL sequence in its intracellular tail defines it as a canonical ITAM-bearing molecule. This motif has been described in many adaptors that are crucial to expression and function of various activating immunoreceptors. After receptor ligation, the two tyrosine of the ITAM are phosphorylated and serve as high affinity docking site for the recruitment of the tandem SH2-containing protein tyrosine kinases ZAP-70 and p72syk, which in turn are activated and phosphorylate many critical downstream signalling components. Along this line, DAP12 participates in cytotoxicity and cytokine production of NK cells [4], [5].
###end p 4
###begin p 5
###xml 174 177 174 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Lanier2">[4]</xref>
###xml 284 285 284 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 290 291 290 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 451 454 451 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Snyder1">[6]</xref>
###xml 456 459 456 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-vanBergen1">[7]</xref>
###xml 573 576 573 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Kumagai1">[8]</xref>
###xml 578 581 578 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Yotsumoto1">[9]</xref>
###xml 769 773 769 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Snyder2">[10]</xref>
###xml 273 279 <span type="species:ncbi:9606">humans</span>
###xml 397 405 <span type="species:ncbi:9606">patients</span>
###xml 464 468 <span type="species:ncbi:10090">mice</span>
Although initially described in NK cells, DAP12 expression has been reported in various hematopoietic cells such as osteoclasts, neutrophils, macrophages and dendritic cells [4]. Interestingly, some T and B cell subsets also express DAP12 under inflammatory conditions. In humans, CD4+ CD28- T cells that express both DAP12 and activating KIR (Killer-cell Ig-like Receptor) have been described in patients suffering from chronic inflammatory diseases [6], [7]. In mice, LPS-stimulated B cells express DAP12 in association with the immunoglobulin-like receptor II (MAIR-II) [8], [9]. Surprisingly, although the expression of ITAM-bearing adaptors is crucial to the expression of various activating immunoreceptors, some DAP12-negative T cells can express activating KIR [10]. These data suggest that an as yet unidentified adaptor molecule could associate with and stabilize cell surface expression of activating KIR in T cells that do not express DAP12.
###end p 5
###begin p 6
###xml 173 177 173 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Hamerman1">[11]</xref>
###xml 179 183 179 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Hamerman2">[12]</xref>
###xml 278 285 278 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 326 330 326 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Sjolin1">[13]</xref>
###xml 293 315 <span type="species:ncbi:10366">murine cytomegalovirus</span>
The function of DAP12 is more complex than originally thought, as it can downregulate TLR-dependent responses in macrophages as well as CD16-dependent responses in NK cells [11], [12]. Similarly, DAP12 down-modulates the cytokine production by plasmacytoid dendritic cell (pDC) in vivo during murine cytomegalovirus infection [13]. Unraveling molecular mechanisms by which DAP12 can induce either activating or inhibiting signals will provide major informations on the fine tuning of immune responses.
###end p 6
###begin p 7
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DAP12</italic>
###xml 180 184 180 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Paloneva1">[14]</xref>
###xml 476 484 476 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 605 609 605 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Cella1">[15]</xref>
###xml 611 615 611 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Kaifu1">[16]</xref>
###xml 617 621 617 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Nataf1">[17]</xref>
###xml 623 627 623 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Paloneva2">[18]</xref>
###xml 17 22 <span type="species:ncbi:9606">human</span>
###xml 192 200 <span type="species:ncbi:9606">patients</span>
###xml 571 579 <span type="species:ncbi:9606">patients</span>
###xml 600 604 <span type="species:ncbi:10090">mice</span>
###xml 641 649 <span type="species:ncbi:9606">patients</span>
Mutations in the human DAP12 gene induce a rare pathology named polycystic lipomembraneous osteodysplasia with sclerosing encephalopathy (PLOSL), also known as Nasu-Hakola disease [14]. These patients do not present any obvious immunological defects, but are affected by severe bone and brain alterations. At early adulthood, first symptoms are pain and frequent fractures in the bone. The bone resorption is controlled by osteoclasts that derived from the monocytic lineage. In vitro the osteoclast differenciation is dramatically affected both in DAP12-deficient PLOSL patients and DAP12-deficient mice [15], [16], [17], [18]. Later PLOSL patients develop frontal lobe syndrome with a diffuse brain inflammation and dementia.
###end p 7
###begin p 8
###xml 710 714 710 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-ErkellerYusel1">[19]</xref>
###xml 716 720 716 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Green1">[20]</xref>
###xml 722 726 722 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Toyabe1">[21]</xref>
###xml 728 732 728 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Yabuhara1">[22]</xref>
###xml 274 277 <span type="species:ncbi:10116">rat</span>
###xml 283 288 <span type="species:ncbi:9606">human</span>
###xml 380 385 <span type="species:ncbi:9606">human</span>
###xml 562 570 <span type="species:ncbi:9606">patients</span>
The combination of neurological, bone and inflammatory disorders which are associated with an alteration of DAP12 expression prompted us to generate a reagent compatible with diverse immunodetection procedures. Here, we describe the production and the characterization of a rat anti-human DAP12 monoclonal antibody. This antibody was used to determine DAP12 expression pattern in human peripheral blood leukocytes of normal subjects. We also investigated the DAP12 expression, in combination with the NK cell receptor repertoire, in systemic lupus erythematosus patients. Indeed, a reduced amount of NK cells, associated with altered functions and a down-modulation of DAP12 have been reported in this disease [19], [20], [21], [22].
###end p 8
###begin title 9
Results
###end title 9
###begin title 10
###xml 28 31 <span type="species:ncbi:10116">rat</span>
###xml 37 42 <span type="species:ncbi:9606">human</span>
Characterization of a novel rat anti-human DAP12 monoclonal antibody
###end title 10
###begin p 11
###xml 337 345 337 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006264-g001">figure 1</xref>
###xml 4 7 <span type="species:ncbi:10116">rat</span>
###xml 504 509 <span type="species:ncbi:9606">human</span>
The rat H10E12F4 IgG1 (thereafter referred as to F4 mAb) was selected by its ability to bind specifically the DAP12 protein in an ELISA test (data not shown). To further analyze its specificity, a flow cytometry analysis of DAP12 expression was performed on RBL cells expressing DAP12 (RBL-CD158j/DAP12) or not (RBL-CD158j). As shown in figure 1, a positive staining by F4 antibody was only detectable in permeabilized DAP12-positive RBL cells. This result was confirmed using lentiviral transduction of human DAP12 cDNA both in DAP12-negative CD8+ T cells and DAP12-negative HEK cells (data not shown). This F4 mAb can be also used to detect DAP12 in Western-Blot as well as in immunohistochemistry assays (data not shown).
###end p 11
###begin title 12
F4 MAb recognizes DAP12 antigen in transfected RBL cells.
###end title 12
###begin p 13
###xml 96 100 96 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Anfossi1">[31]</xref>
###xml 28 31 <span type="species:ncbi:10116">rat</span>
###xml 184 189 <span type="species:ncbi:9606">human</span>
###xml 237 242 <span type="species:ncbi:9606">human</span>
###xml 579 583 <span type="species:ncbi:9925">goat</span>
###xml 589 592 <span type="species:ncbi:10116">rat</span>
Stable transfectants of the rat basophilic leukemia cell line (RBL) have been described earlier [31]. In brief, RBL-CD158j and RBL-CD158j/DAP12 have been obtained by transfection with human cDNAs encoding CD158j alone or both CD158j and human DAP12, respectively. RBL cells were fixed by incubation with 2% paraformaldehyde at room temperature. Then the cells were permeabilized by Permwash treatment (Beckton Dickinson) before staining with 50 microg/ml irrelevant or F4 antibody on ice for 30 min. After three washes in cold PBS, the cells were incubated 1:100 FITC-conjugated goat anti-rat immunoglobulins.
###end p 13
###begin title 14
###xml 70 78 <span type="species:ncbi:9606">patients</span>
DAP-12 expression pattern in healthy and systemic lupus erythematosus patients
###end title 14
###begin p 15
###xml 630 632 626 628 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">24</sub>
###xml 639 641 632 634 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 785 786 770 771 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 805 806 790 791 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 826 827 811 812 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 853 854 830 831 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 879 881 852 854 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">24</sub>
###xml 899 908 872 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006264-g002">Figure 2A</xref>
###xml 1010 1016 983 989 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 1025 1028 998 1001 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 1046 1055 1019 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006264-g002">Figure 2B</xref>
###xml 133 138 <span type="species:ncbi:10090">mouse</span>
###xml 143 148 <span type="species:ncbi:9606">human</span>
###xml 303 309 <span type="species:ncbi:9606">humans</span>
Since the original description of DAP12 expression in NK cells, a broader expression among other immune cells has also been found in mouse and human, both in myeloid and lymphoid cells, and many DAP12-associated activating membrane receptors have been described. However, data about DAP12 expression in humans relies on Western blot and microarrays studies. Thus, the F4 mAb was used to provide additional data about the expression of the polypeptide DAP12 in leukocytes from healthy individuals. Whole blood sample from healthy donors were stained in a first step by lymphocytes surface markers (CD4, CD8, CD19, CD56, CD3, Valpha24, Vbeta12, TCRgammadelta). Then the cells were permeabilized and stained by Alexa 647-conjugated F4 antibody. DAP12 expression was barely detected in CD8+ T lymphocytes, CD4+ T lymphocytes, CD19+ B lymphocytes, gammadelta+ T lymphocytes and Valpha24 NKT lymphocytes (Figure 2A). By contrast DAP12 expression was detected in the NK cell population with no difference between CD56bright and CD56dim sub-populations (Figure 2B).
###end p 15
###begin title 16
Analysis of DAP12 expression on leukocytes.
###end title 16
###begin p 17
###xml 333 335 329 331 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">24</sub>
###xml 731 732 719 720 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 771 772 759 760 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 776 777 764 765 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 816 817 804 805 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 821 822 809 810 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 915 916 887 888 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 920 921 892 893 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 928 930 896 898 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">24</sub>
###xml 930 931 898 899 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1024 1025 992 993 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1030 1031 998 999 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1138 1139 1106 1107 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1152 1153 1120 1121 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1161 1162 1129 1130 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1307 1308 1275 1276 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1313 1323 1281 1291 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim to neg</sup>
###xml 1327 1330 1295 1298 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 1417 1420 1385 1388 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 1445 1449 1413 1417 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 1495 1496 1463 1464 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 130 135 <span type="species:ncbi:10090">mouse</span>
Whole-blood samples from 10 healthy donors were collected and stained in a first step with several surface markers. The following mouse mAb from Immunotech-Beckman-Coulter were used: FITC-CD19 (J4.119), ECD-CD3 (UCHT1), FITC-CD16 (3G8), FITC-CD4 (13B8.2), FITC-CD8 (B9.11), FITC-CD33 (D3HL60.251), PECy7-CD14 (RMO52), FITC-TCR Valpha24 (C15), PE-TCR pangammadelta (IMMU510), PECy7-CD56 (N901), PE-ILT3 ou PE-CD85k (ZM3.8). The blood was then treated with the IntraPrepTM permeabilization reagent and stained with DAP-12-Alexa 647-conjugated antibody (H10E12F4) (Immunotech-Beckman-Coulter). A. After gating lymphocyte population using SSC/FSC plot, T and B lymphocyte sub-populations were defined as follows: B lymphocytes are CD19+ cells, auxiliary T lymphocytes are CD3+/CD4+ cells, cytotoxic T lymphocytes are CD3+/CD8+ cells, gammadeltaT lymphocytes are TCRgammadelta-positive cells and NKT lymphocytes are CD56+/CD3+/Valpha24+. B. After gating lymphocyte population using SSC/FSC plot, total NK cells are defined as CD3-/CD56+ cells and analyzed according to their level of CD56 expression. C. Monocytes were defined on the size/CD33+ gate as CD16+ or CD14+. Expression of DAP12 was analysed in these double-positive cells that can express or not the CD16 molecule. Dendritic cells were defined as ILT3+/CD14dim to negCD16neg within the lymphocyte and monocyte gate and further characterized as plasmacytoid CD33low DC and conventional CD33high DC. Neutrophils were defined on the size/CD16+ gate. D. Schematic representation of the expression of DAP12 by leukocyte subsets from healthy individuals.
###end p 17
###begin p 18
###xml 137 146 137 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006264-g002">Figure 2C</xref>
###xml 374 375 371 372 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 384 385 381 382 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 560 561 551 552 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 566 567 557 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 572 573 563 564 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 634 637 625 628 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 661 665 652 656 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
The expression of DAP12 in other cells involved in innate immunity and expressing several DAP12-associated receptors was then evaluated (Figure 2C). Among these cells, monocytes express TREM-1, SIRP-beta, MDL-1 and IREM-2 receptors. Thus, F4 staining on distinct monocyte sub-populations that co-expressed CD14 and CD33 molecules was analysed. A strong staining of both CD16+ and CD16- monocyte subsets was observed. Dendritic cells (DC) also express several DAP12-associated receptors, such as PIRL-beta, SIRP-beta, IREM-2 and TREM-2. DC were defined as ILT-3+/CD14+/CD16- cells. DAP12 was highly expressed both in plasmocytoid (CD33low) and conventional (CD33high) DC sub-populations. Finally neutrophils are DAP12-positive cells.
###end p 18
###begin p 19
###xml 442 449 430 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006264-t001">Table 1</xref>
###xml 978 981 958 961 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 990 996 970 976 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 1029 1036 1009 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006264-t002">Table 2</xref>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
###xml 137 145 <span type="species:ncbi:9606">patients</span>
###xml 360 368 <span type="species:ncbi:9606">patients</span>
###xml 536 544 <span type="species:ncbi:9606">patients</span>
###xml 801 809 <span type="species:ncbi:9606">patients</span>
###xml 863 871 <span type="species:ncbi:9606">patients</span>
Since it was previously described a lower NK cell number in SLE patients, we have quantified and compared the leukocyte subsets from SLE patients and control individuals. NK absolute counts and percentage of total lymphocyte were first compared to our large control group of 92 healthy donors. The mean of NK absolute counts was significantly decreased in SLE patients compared to controls (106/microl+/-15 versus 259/microl+/-14, p<0.0001) (Table 1). The NK cell percentage of total lymphocytes was also significantly decreased in SLE patients compared to this control group (7.81%+/-1.19 versus 12.01%+/-0.59, p = 0.011). However, when compared to the control group of 10 healthy donors, used for the NK cell phenotype analysis, there was only a trend toward a decrease in NK cell percentage in SLE patients that did not reach significance (7.81%+/-1.19 in SLE patients compared to 11.59%+/-2.25 in controls, p = 0.12). There is no significant change in the proportion of CD56dim and CD56bright subsets between the two groups (Table 2).
###end p 19
###begin title 20
###xml 38 46 <span type="species:ncbi:9606">patients</span>
Number of NK cells in SLE and control patients.
###end title 20
###begin p 21
###xml 137 145 <span type="species:ncbi:9606">patients</span>
Absolute numbers and percentage of NK cells among total lymphocytes are indicated for the control group (n = 92) and the SLE group of 13 patients.
###end p 21
###begin title 22
###xml 73 81 <span type="species:ncbi:9606">patients</span>
Percentage of leukocytes subsets and DAP12 expression in SLE and control patients.
###end title 22
###begin p 23
###xml 78 84 78 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 93 96 93 96 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
Both percentage of NK cells among total lymphocytes and percentage of the CD56bright and CD56dim subsets among NK cells are indicated. The percentage of dendritic cells, monocytes and neutrophils among the leukocytes are given. Statistically significant values are shown in bold.
###end p 23
###begin p 24
###xml 302 309 294 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006264-t002">Table 2</xref>
###xml 130 138 <span type="species:ncbi:9606">patients</span>
###xml 399 407 <span type="species:ncbi:9606">patients</span>
The quantification of other leukocytes subsets has shown that the percentage of circulating DC was significantly decreased in SLE patients compared to controls, considering both plasmacytoid DC (0.16+/-0.08 versus 0.24+/-0.074, p = 0.04) or conventional DC (0.19+/-0.09 versus 0.32+/-0.09, p = 0.003) (Table 2). On the contrary, the percentages of neutrophils or monocytes were not different in SLE patients compared to controls.
###end p 24
###begin p 25
###xml 605 612 601 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006264-t002">Table 2</xref>
###xml 704 711 700 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006264-t002">Table 2</xref>
###xml 112 120 <span type="species:ncbi:9606">patients</span>
It was previously described by western-blot analysis a down-regulation of DAP12 expression in NK cells from SLE patients. In addition, DAP12 is also expressed by other leukocytes such as DC which have been clearly involved in lupus physiopathogeny. This prompted us to extend on leukocyte subsets the analysis of DAP12 expression in SLE. The number of DAP12-positive NK cells was slightly decreased compared to our control group of healthy subject (96.67%+/-2.02 versus 97.66%+/-3.23, p = 0.02) (data not shown). Conversely, there is no significant modulation of the MFI for DAP12 expression by NK cells (Table 2). The expression of DAP12 in DCs, monocytes and neutrophils are similar in the two groups (Table 2).
###end p 25
###begin title 26
###xml 60 68 <span type="species:ncbi:9606">patients</span>
NK cell receptor repertoire of systemic lupus erythematosus patients
###end title 26
###begin p 27
###xml 60 68 <span type="species:ncbi:9606">patients</span>
It has been shown that NK cell functions are altered in SLE patients. A modulation in the expression of activatory and inhibitory NK cell receptors, implicated in the tuning of NK cell activation, could be associated with a decrease in NK cell functions. Moreover DAP12 is crucial to signalling of many NK cell activatory receptors.
###end p 27
###begin p 28
###xml 308 316 308 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006264-g003">figure 3</xref>
###xml 404 405 404 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 285 293 <span type="species:ncbi:9606">patients</span>
###xml 637 645 <span type="species:ncbi:9606">patients</span>
Phenotypical characterization of NK cells was performed by analyzing the expression of many receptors such as NKp46, NKp30, NKp44, NKG2D, CD244, CD2, CD16, CD69, CD159a, CD158a/h, CD158b1/b2/j, CD158e1/e2, CD158i and NKG2A. The results show only minor phenotypical changes between SLE patients and controls (figure 3). There is a significant decrease of CD16 MFI (p = 0.03) and of the proportion of CD244+ NK cells (p = 0.002) associated with an increase of the CD158 b1/b2/j MFI (p = 0.02) in the SLE group. No difference for the expressions of NKp46, NKp30, NKp44, CD2, CD69, NKG2A, CD158a/h, CD158e1/e2 and CD158i was observed in SLE patients compared to controls.
###end p 28
###begin title 29
###xml 44 52 <span type="species:ncbi:9606">patients</span>
NK cell receptors percentage and MFI in SLE patients and controls.
###end title 29
###begin p 30
###xml 243 244 243 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 127 135 <span type="species:ncbi:9606">patients</span>
Cell surface expression of indicated molecules on NK cells within peripheral blood lymphocytes from controls (squares) and SLE patients (triangles) are given as percentage of total NK cells and MFI. Horizontal bars indicate median values. The p value is mentioned above a given NK cell subset when a statistically significant difference is observed between the two groups.
###end p 30
###begin title 31
Discussion
###end title 31
###begin p 32
###xml 20 23 <span type="species:ncbi:10116">rat</span>
###xml 66 71 <span type="species:ncbi:9606">human</span>
###xml 171 176 <span type="species:ncbi:9606">human</span>
###xml 265 273 <span type="species:ncbi:9606">patients</span>
We have generated a rat monoclonal antibody (F4) directed against human DAP12 for which the specificity was validated in three independents transfection models. This anti-human DAP12 monoclonal antibody represents a powerful tool to investigate DAP12 expression in patients.
###end p 32
###begin p 33
###xml 239 248 239 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006264-g002">Figure 2D</xref>
###xml 325 329 325 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Su1">[23]</xref>
###xml 86 91 <span type="species:ncbi:9606">human</span>
This report is the first description of basal expression of DAP12 protein in distinct human leukocyte subpopulations from healthy individuals. These results validate the restricted expression of DAP12 in cells involved in innate immunity (Figure 2D) and are consistent with public databases of transcript pattern of DAP12 () [23].
###end p 33
###begin p 34
###xml 755 760 <span type="species:ncbi:10090">mouse</span>
###xml 799 804 <span type="species:ncbi:9606">human</span>
###xml 809 814 <span type="species:ncbi:10090">mouse</span>
In some individuals, a dull staining with the F4 mAb was detected. This F4 staining was abrogated upon preincubation of F4 antibody with the GST-DAP12 immunogen and was unchanged after preincubation of F4 antibody with an irrelevant GST protein, suggesting a specific but weak binding (data not shown). Then, we hypothesized that alternative transcripts of DAP12, that are not detected by classical RT-PCR, are recognized by the F4 mAb. To address this issue, specific primers of DAP12 were designed to amplify from exon 1 to 3, 1 to 4, 1 to 5 and 3 to 5. Using these primers, no transcripts were detected in cells known as DAP12 negative (data not shown). The F4 mAb could also cross-react with an as yet unknown protein. Since F4 mAb does not recognize mouse DAP12, we aligned proteic sequence of human and mouse intracellular domains of DAP12 and we identified species specific amino acid sequences. Most of gaps were found in the aminoterminal part of the intracellular domain. This region was blasted using NCBI server, but no significant hit was found. At this time, we are not able to explain the dull staining observed in some DAP12-negative cells. We cannot formally exclude the existence of another adaptor that could be recognized by F4 mAb with a weaker affinity compared to DAP12.
###end p 34
###begin p 35
###xml 17 20 <span type="species:ncbi:10116">rat</span>
To conclude, the rat IgG1monoclonal antibody F4 allows an efficient detection of DAP12 expression in monocytes, dendritic cells, neutrophils and natural killer cells. Indeed, in some inflammatory conditions, it would be a useful reagent to monitor DAP12 expression in B and T cell populations.
###end p 35
###begin p 36
###xml 162 168 162 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 210 214 210 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Schepis1">[24]</xref>
###xml 398 404 398 404 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 48 56 <span type="species:ncbi:9606">patients</span>
###xml 201 209 <span type="species:ncbi:9606">patients</span>
The circulating NK cells from our cohort of SLE patients presented only mild phenotypical changes when compared to NK cells from controls. An increase of the CD56bright subset has been reported in SLE patients [24]. This NK cell subset is of interest in SLE because it represents the main NK cells found in secondary lymphoid tissues and inflamed tissues. We also report a weak increase of the CD56bright subset, however this change is not significant due to the great interindividual variability. This discrepancy could be explained by the low activity index of SLE in our cohort.
###end p 36
###begin p 37
###xml 208 212 208 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Pellett1">[25]</xref>
###xml 481 482 481 482 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 319 327 <span type="species:ncbi:9606">patients</span>
###xml 511 519 <span type="species:ncbi:9606">patients</span>
Activation of NK cells is finely tuned by the expression of MHC class I NK cell receptors. Moreover susceptibility to some autoimmune and inflammatory diseases have been genetically linked to these receptors [25]. In our study, the levels of NKG2A (CD159a), CD158a/h, CD158e1/e2, CD158i expression by NK cells from SLE patients were in the normal range with the exception of the CD158b1/b2/j receptors for which an increased MFI is observed. However, the percentage of CD158b1/b2/j+ NK cells was similar in SLE patients and controls.
###end p 37
###begin p 38
###xml 212 216 212 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Izumi1">[26]</xref>
###xml 650 651 650 651 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 855 863 <span type="species:ncbi:9606">patients</span>
Along the same line, the abnormal expression of the Natural Cytotoxicity Receptors (NCR) reported in primary Sjogren syndrome was proposed to explain the decrease of NK cell cytotoxity in this autoimmune disease [26]. By contrast to these results, the expression of NKp44 (data not shown), NKp46 and NKp30 were not significantly different from controls. We also investigated the expression of CD244, CD16 and CD2. Although the percentage of NK cells expressing CD244 was slightly decreased, there is no difference in the MFI. Moreover, while the MFI of the CD16 staining was also slightly decreased, there is no modification of the percentage of CD16+ NK cells. At last, the expression of CD2 is identical in the two groups. Thus, altogether these results show the absence of a major modulation of the expression of NK cell receptors in our cohort of SLE patients.
###end p 38
###begin p 39
###xml 452 464 452 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Toyabe et al</italic>
###xml 613 617 613 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Toyabe1">[21]</xref>
###xml 282 290 <span type="species:ncbi:9606">patients</span>
###xml 357 365 <span type="species:ncbi:9606">patients</span>
###xml 533 541 <span type="species:ncbi:9606">patients</span>
###xml 580 586 <span type="species:ncbi:9986">rabbit</span>
###xml 592 597 <span type="species:ncbi:9606">human</span>
###xml 649 657 <span type="species:ncbi:9606">patients</span>
###xml 781 788 <span type="species:ncbi:9606">patient</span>
Since the DAP12 adaptor molecule is used by many receptors to transduce activating signals, its expression was analysed in distinct leukocyte subpopulations by flow cytometry using the F4 mAb. No significant changes were found both in NK cells and leukocyte subpopulations from SLE patients compared to controls. Only few NK cells are DAP12-negative in SLE patients and the percentage of expression are very close to controls. Contrary to our results, Toyabe et al. have reported a decreased expression of DAP12 in NK cells from SLE patients by using western blot analysis with a rabbit anti-human DAP12 antibody [21]. Similarly to our study, their patients were mostly untreated and they displayed a relatively low SLEDAI score, suggesting that this discrepancy is not related to patient characteristics but rather to the methods used for DAP12 detection in NK cells.
###end p 39
###begin p 40
###xml 392 396 392 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Costello1">[27]</xref>
###xml 226 234 <span type="species:ncbi:9606">patients</span>
To conclude, our results confirm that the basal expression of DAP12 is restricted to cells of innate immunity in healthy individuals. In addition, this study shows that the functional deficiency of NK cell cytotoxicity in SLE patients is not related to an abnormal expression of the NK cell receptors or DAP12 protein, as it has been previously shown with NCRs in acute myelogenous leukaemia [27].
###end p 40
###begin title 41
Materials and Methods
###end title 41
###begin title 42
###xml 64 69 <span type="species:ncbi:9606">human</span>
Generation and characterization of a novel mAb directed against human DAP12
###end title 42
###begin p 43
###xml 355 379 355 379 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;GGGATCCCGGCTGGTCCCT-3&#8242;</named-content>
###xml 395 423 395 423 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CGAATTCTGTCATGATTCGGGC-3&#8242;</named-content>
###xml 929 933 925 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Vely1">[28]</xref>
###xml 69 72 <span type="species:ncbi:10116">rat</span>
###xml 104 108 <span type="species:ncbi:10116">Rats</span>
###xml 201 206 <span type="species:ncbi:9606">human</span>
###xml 288 293 <span type="species:ncbi:9606">human</span>
###xml 654 658 <span type="species:ncbi:10116">Rats</span>
###xml 971 975 <span type="species:ncbi:10116">rats</span>
Hybridomas were generated by fusion of splenocytes from an immunized rat with the Ag8-X63 plasmocytoma. Rats Lou (Harlan) were immunized with a GST-DAP12 protein containing the intracellular moiety of human DAP12 fused to the GST protein. The coding sequence of the intracellular part of human DAP12 was obtained by PCR using specific primers (5' primer, 5'GGGATCCCGGCTGGTCCCT-3' and 3' primer, 5'-CGAATTCTGTCATGATTCGGGC-3') and cloned in BamHI and EcoRI restriction sites of pGEX-4-T1 vector (GE Healthcare). Bacteria transformation and fusion protein production and purification were performed according to manufacturer's instructions (GE Healthcare). Rats were subcutaneously immunized at 3-weeks intervals with 100 microg of purified GST-DAP12 solution emulsified in an equal volume of Freund's adjuvant (complete for the first injection and uncomplete for the following boosts). The fusion protocol was previously described [28]. Briefly, splenocytes from immunized rats were fused with Ag8-X63 plasmocytoma cells. Ten days after the fusion, the presence of specific antibodies in supernatants of hybridoma cultures was evaluated by ELISA. Positive hybridomas were cloned twice by limiting dilution in 96-well culture plates. Purification of the monoclonal antibody was performed by protein G-sepharose affinity chromatography.
###end p 43
###begin title 44
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 44
###begin p 45
###xml 361 368 361 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006264-t003">Table 3</xref>
###xml 456 460 456 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Bombardier1">[29]</xref>
###xml 964 968 964 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006264-Pascal1">[30]</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 203 211 <span type="species:ncbi:9606">patients</span>
###xml 311 319 <span type="species:ncbi:9606">patients</span>
###xml 1196 1203 <span type="species:ncbi:9606">patient</span>
Patients enrolled in the study (n = 13) were recruited from our Department of Internal Medicine. They presented with SLE and fulfilled the American Rheumatism Association 1982 revised criteria, except 2 patients presenting with only 3 criteria and thus considered as lupus-like syndrome. Characteristics of the patients and ongoing treatments are summarized in Table 3. Disease activity was assessed by a modified SLE disease activity index (SLEDAI) score [29]. 10 healthy volunteers (controls) were recruited from the CPCET (Centre de Pharmacologie Clinique et d'Evaluations Therapeutiques). CPCET is an official facility from our hospital where healthy volunteers are enrolled in studies after written informed consent is obtained in accordance with ethics and law. For NK cell absolute numbers and percentage of total lymphocytes, additional statistical comparison was made with values obtained in a previously reported large control cohort of healthy subjects [30]. This study did not require the approvement of an ethical committee as it was performed without any supplemental blood prelevement. The analysis were performed on blood samples used for routine analysis during the follow-up. A patient written informed consent was obtained in accordance with the French law.
###end p 45
###begin title 46
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients characteristics.
###end title 46
###begin p 47
###xml 139 146 <span type="species:ncbi:9606">patient</span>
###xml 259 267 <span type="species:ncbi:9606">patients</span>
###xml 498 505 <span type="species:ncbi:9606">patient</span>
Quantification of total White blood cells (WBC), total lymphocytes (Ly) and NK cells are indicated in cells per microl. Treatment for each patient is shown: MMF for mycophenolate mofetil, H for hydroxychloroquine and P for prednisone (at time of analysis all patients received </=10 mg/day of prednisone). Main biological characteristics of autoantibodies are shown: antinuclear antibodies (ANA) titer, type of ANA and titer of anti-dsDNA autoantibodies (N<7). The number of ACR criterias for each patient is indicated.
###end p 47
###begin title 48
MAb and Flow cytometry
###end title 48
###begin p 49
###xml 508 509 508 509 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 513 514 513 514 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 600 601 600 601 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 606 616 606 616 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim to neg</sup>
###xml 620 623 620 623 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 713 716 713 716 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 741 745 741 745 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 786 787 786 787 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 800 801 800 801 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 809 810 809 810 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 853 854 853 854 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 14 19 <span type="species:ncbi:10090">mouse</span>
The following mouse mAbs were used: ECD-CD3 (UCHT1), FITC-CD16 (3G8), FITC-CD4 (13B8.2), FITC-CD8 (B9.11), FITC-CD33 (D3HL60.251), PECy7-CD56 (N901), PE-ILT3 ou PE-CD85k (ZM3.8), PE-NKG2D (ON72), PE-NKp30 (Z25), PE-NKp44 (Z231), PE-NKp46 (Bab281), PE-CD159a/NKG2A (Z199), PE-CD158a/h (EB6B), PE-CD158b1/b2/j (GL183), PE-CD158e1/e2 (Z27.3.7), PE-CD158i (FES172), PE-CD69 (TP1.55.3), PE-CD2 (39C1.5), PE-CD244 (C1.7) and DAP-12 Alexa 647 (H10E12F4), (all from Beckman Coulter). NK cells were defined as the CD3-CD56+ cells within the lymphocyte size/structure gate. Dendritic cells were defined as ILT3+/CD14dim to negCD16neg within the lymphocyte and monocyte gate and further characterized as plasmacytoid DC CD33low and conventional DC CD33high. Monocytes were defined on the size/CD33+ gate as CD16+ or CD14+. Neutrophils were defined on the size/CD16+ gate.
###end p 49
###begin p 50
Whole blood samples from donors were collected and stained in a first step with several surface markers. The blood was then treated with a permeabilization reagent (IntraPreptrade mark permeabilization reagent IM2388) and stained with DAP-12 Alexa-647 conjugated antibody. All samples were analyzed on a Cytomics FC500 flow cytometer using CXP software (Beckman Coulter, Miami, US).
###end p 50
###begin title 51
Statistical analysis
###end title 51
###begin p 52
Graphic representation and statistical analysis of NK cell phenotype were obtained using Graphpad Prism software (San Diego, CA). Comparison of distributions was performed using the Mann-Whitney U-tests. Results were considered as significant with a p<0.05.
###end p 52
###begin p 53
We thank Pr Eric Vivier for his relevant comments on this work.
###end p 53
###begin title 54
References
###end title 54
###begin article-title 55
Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells.
###end article-title 55
###begin article-title 56
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human killer cell activatory receptors for MHC class I molecules are included in a multimeric complex expressed by natural killer cells.
###end article-title 56
###begin article-title 57
###xml 63 68 <span type="species:ncbi:10090">mouse</span>
Gene structure, expression pattern, and biological activity of mouse killer cell activating receptor-associated protein (KARAP)/DAP-12.
###end article-title 57
###begin article-title 58
The ITAM-bearing transmembrane adaptor DAP12 in lymphoid and myeloid cell function.
###end article-title 58
###begin article-title 59
KARAP/DAP12/TYROBP: three names and a multiplicity of biological functions.
###end article-title 59
###begin article-title 60
Selective activation of the c-Jun NH2-terminal protein kinase signaling pathway by stimulatory KIR in the absence of KARAP/DAP12 in CD4+ T cells.
###end article-title 60
###begin article-title 61
Phenotypic and functional characterization of CD4 T cells expressing killer Ig-like receptors.
###end article-title 61
###begin article-title 62
###xml 108 114 <span type="species:ncbi:10090">murine</span>
Identification and characterization of a new pair of immunoglobulin-like receptors LMIR1 and 2 derived from murine bone marrow-derived mast cells.
###end article-title 62
###begin article-title 63
Paired activating and inhibitory immunoglobulin-like receptors, MAIR-I and MAIR-II, regulate mast cell and macrophage activation.
###end article-title 63
###begin article-title 64
Stimulatory killer Ig-like receptors modulate T cell activation through DAP12-dependent and DAP12-independent mechanisms.
###end article-title 64
###begin article-title 65
Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12.
###end article-title 65
###begin article-title 66
Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12.
###end article-title 66
###begin article-title 67
DAP12 signaling regulates plasmacytoid dendritic cell homeostasis and down-modulates their function during viral infection.
###end article-title 67
###begin article-title 68
Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts.
###end article-title 68
###begin article-title 69
Impaired differentiation of osteoclasts in TREM-2-deficient individuals.
###end article-title 69
###begin article-title 70
###xml 88 92 <span type="species:ncbi:10090">mice</span>
Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice.
###end article-title 70
###begin article-title 71
###xml 54 58 <span type="species:ncbi:10090">mice</span>
Brain and bone damage in KARAP/DAP12 loss-of-function mice correlate with alterations in microglia and osteoclast lineages.
###end article-title 71
###begin article-title 72
DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features.
###end article-title 72
###begin article-title 73
###xml 40 48 <span type="species:ncbi:9606">patients</span>
Lymphocyte subsets in a large cohort of patients with systemic lupus erythematosus.
###end article-title 73
###begin article-title 74
###xml 44 52 <span type="species:ncbi:9606">patients</span>
###xml 125 133 <span type="species:ncbi:9606">patients</span>
Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients.
###end article-title 74
###begin article-title 75
###xml 62 70 <span type="species:ncbi:9606">patients</span>
Decreased DAP12 expression in natural killer lymphocytes from patients with systemic lupus erythematosus is associated with increased transcript mutations.
###end article-title 75
###begin article-title 76
A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus.
###end article-title 76
###begin article-title 77
###xml 28 33 <span type="species:ncbi:9606">human</span>
###xml 38 43 <span type="species:ncbi:10090">mouse</span>
Large-scale analysis of the human and mouse transcriptomes.
###end article-title 77
###begin article-title 78
Increased proportion of CD56(bright) natural killer cells in active and inactive systemic lupus erythematosus.
###end article-title 78
###begin article-title 79
KIRs and autoimmune disease: studies in systemic lupus erythematosus and scleroderma.
###end article-title 79
###begin article-title 80
Characterization of peripheral natural killer cells in primary Sjogren's syndrome: impaired NK cell activity and low NK cell number.
###end article-title 80
###begin article-title 81
###xml 81 89 <span type="species:ncbi:9606">patients</span>
Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia.
###end article-title 81
###begin article-title 82
###xml 43 48 <span type="species:ncbi:9606">human</span>
A new set of monoclonal antibodies against human Fc gamma RII (CD32) and Fc gamma RIII (CD16): characterization and use in various assays.
###end article-title 82
###begin article-title 83
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.
###end article-title 83
###begin article-title 84
Comparative analysis of NK cell subset distribution in normal and lymphoproliferative disease of granular lymphocyte conditions.
###end article-title 84
###begin article-title 85
Contrasting roles of DAP10 and KARAP/DAP12 signaling adaptors in activation of the RBL-2H3 leukemic mast cell line.
###end article-title 85
###begin p 86
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 86
###begin p 87
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by institutional resources provided by INSERM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 87

